GlaxoSmithKlineThe Impact of Medicines: Sustainability in Environment, Health and Safety Report 2002
Reporting Front PageDownloads
EHS 2002 home

About this report

Executive statements

Framework

Issues

Performance

Fines, penalties and serious events

Fatalities and serious occupational injuries and illnesses

EHS costs

Energy consumption

Water usage

Air emissions

Waste generation and management

Health and safety

Verification statement

Index

Energy consumption
Previous
Next
 
 
Energy Consumption

The measure of energy is defined as all energy consumed at GSK facilities during the year in the form of electricity and steam imported and fuels burned in fixed combustion equipment on site, including emergency generators. Fuels used for onsite transport have not been included but fuels used to generate steam and electricity on site have been included.

The 2001 baseline originally reported for energy consumption was 21.4 million gigajoules. This included electricity and steam imported and fuels burned in fixed combustion equipment as well as onsite transport fuels and energy generated on site. The revised 2001 baseline, 20.7 million gigajoules, does not include fuels used for onsite transport and does not double count fuels used onsite to generate electricity and steam. In 2002, GSK consumed 20.1 million gigajoules of energy. Compared to 20.7 million gigajoules in 2001, this is a decrease of 2.9%. Nearly 60% of energy consumed is through the burning of fuel to support manufacturing processes and heating buildings and other uses not related to transportation. Forty percent (40%) of energy consumed is electricity.

A target has been set to reduce energy consumption from site activities by 8% on a per unit sales basis by the end of 2005.

 

 


Energy Consumption by Business


R&D Energy Programmes

In 2002 a group of eight of the UK Pharmaceutical R&D sites consumed 8.81% less energy, than in 2001 and emitted approximately 19,900 fewer tonnes of CO2 to the atmosphere. This result was delivered by "energy management teams" that drove energy saving initiatives by reviewing operational requirements and efficiencies and promoting energy conservation through energy awareness, auditing and energy saving campaigns. For instance, the team at Stevenage targeted the air handling ventilation system in a microbiology building. Their review revealed a system of six 75 kW air-handling fans, feeding into a common manifold duct system providing air distribution throughout the building. Originally air volume control was provided by inlet guide vanes, which were inefficient in operation and did not provide good control for reduced air flows where required. They replaced the existing fan motors with high efficiency motors, installed variable speed drives on the fan motors and removed the inlet guide vane mechanisms to improve operational efficiency. Overall the air handling units used 15% less energy and provided better control of air volume during "unoccupied" periods. This project has resulted in a potential saving of approximately 460,000 kWh per annum, representing savings of around 330 tonnes of C02 emissions.



Previous

Next


Top


EHS 2002 Home | Reporting Front Page | Downloads | Main Site

 
Updated July 21, 2003 - © 2005 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement